Evidence map›Paper›PMID 32366466›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2020

Levothyroxine prescribing and laboratory test use after a minor change in reference range for thyroid-stimulating hormone.

Christopher Symonds, Gregory Kline, Inelda Gjata, Marianne Sarah Rose, Maggie Guo, Lara Cooke, Christopher Naugler

Open access · goldAbstract read
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. What happens when laboratory reference ranges change?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christopher SymondsDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Gregory KlineDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Inelda GjataDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Marianne Sarah RoseDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Maggie GuoDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Lara CookeDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta.
Christopher NauglerDepartment of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cumming School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta. cjsymond@ucalgary.ca.
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrescribing of levothyroxine and rates of thyroid function testing may be sensitive to minor changes in the upper limit of the reference range for thyroid-stimulating hormone (TSH) that increase the proportion of abnormal results. We evaluated the population-level change in levothyroxine prescribing and TSH testing after a minor planned decrease in the upper limit of the reference range for TSH in a large urban centre with a single medical laboratory.

methodsUsing provincial administrative data, we compared predicted volumes of TSH tests with actual TSH test volumes before and after a planned change in the TSH reference range. We also determined the number of new levothyroxine prescriptions for previously untreated patients and the rate of changes to the prescribed dose for those on previously stable, long-term levothyroxine therapy before and after the change in the TSH reference range.

resultsBefore the change in the TSH reference range, actual and predicted monthly volumes of TSH testing followed an identical course. After the change, actual test volumes exceeded predicted test volumes by 7.3% (95% confidence interval [CI] 5.3%-9.3%) or about 3000 to 5000 extra tests per month. The proportion of patients with newly "abnormal" TSH results almost tripled, from 3.3% (95% CI 3.2%-3.4%) to 9.1% (95% CI 9.0%-9.2%). The rate of new levothyroxine prescriptions increased from 3.24 (95% CI 3.15-3.33) per 1000 population in 2013 to 4.06 (95% CI 3.96-4.15) per 1000 population in 2014. Among patients with preexisting stable levothyroxine therapy, there was a significant increase in the number of dose escalations (

interpretationOur findings suggest that clinicians may have responded to mildly elevated TSH results with new or increased levothyroxine prescriptions and more TSH testing. Knowledge translation efforts may be useful to accompany minor changes in reference ranges.

Indexed as

AlbertaClinical Laboratory TechniquesHumansHypothyroidismPractice Patterns, Physicians'Reference ValuesThyrotropinThyroxineThyrotropinThyroxine

Identifiers

PMID32366466
PMCPMC7207175
OpenAlexW3022826565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.